Adlai Nortye's Buparlisib, a pan-PI3K inhibitor, is in Phase III trials for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) after anti-PD-(L)1 treatment.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.